PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts give PepGen a “Moderate Buy” consensus: six of seven covering firms rate the stock a buy, while one rates it a sell. The average 12-month price target is $11.50.
• Institutional ownership is substantial at 58.01%. Several funds increased their positions, including Pictet Asset Management, ADAR1 Capital Management, and Commodore Capital.
• PepGen shares opened at $2.99, compared with a 12-month range of $1.13 to $7.80. The company reported a quarterly loss of $0.26 per share, beating estimates of a $0.28 loss.

PepGen, Inc. (NASDAQ:PEPG - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $11.50.

Several research firms have issued reports on PEPG. Wedbush lowered their price target on shares of PepGen from $5.00 to $4.00 and set an "outperform" rating for the company in a report on Wednesday, May 13th. HC Wainwright reaffirmed a "buy" rating on shares of PepGen in a research report on Thursday, May 21st. Weiss Ratings lowered PepGen from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 2nd. Craig Hallum started coverage on PepGen in a research note on Tuesday, June 16th. They set a "buy" rating and a $11.00 target price for the company. Finally, Wall Street Zen raised shares of PepGen from a "sell" rating to a "hold" rating in a research report on Sunday, June 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Pictet Asset Management Holding SA boosted its position in shares of PepGen by 181.0% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,352,424 shares of the company's stock worth $8,804,000 after purchasing an additional 871,059 shares in the last quarter. Kalehua Capital Management LLC bought a new stake in PepGen in the 1st quarter valued at about $1,770,000. ADAR1 Capital Management LLC raised its stake in PepGen by 4,263.6% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,607,638 shares of the company's stock worth $2,846,000 after buying an additional 1,570,796 shares during the period. Commodore Capital LP boosted its holdings in PepGen by 31.6% in the first quarter. Commodore Capital LP now owns 4,475,000 shares of the company's stock worth $7,921,000 after acquiring an additional 1,075,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in PepGen by 94.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company's stock valued at $73,000 after acquiring an additional 5,453 shares during the period. 58.01% of the stock is owned by institutional investors.

PepGen Stock Up 0.3%

Shares of NASDAQ:PEPG opened at $2.99 on Friday. The firm has a market cap of $207.09 million, a P/E ratio of -2.28 and a beta of 1.89. PepGen has a 12-month low of $1.13 and a 12-month high of $7.80. The business has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $3.04.

PepGen (NASDAQ:PEPG - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. As a group, equities research analysts expect that PepGen will post -1.11 EPS for the current year.

PepGen Company Profile

PepGen, Inc NASDAQ: PEPG is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source